B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Publisher: La Merie Publishing
Pages: 39
Format: PDF
Product Line:
Brief Report
Product Code: LMBR0012
Release Date: August of 2016

500.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the

  • Scientific rationale for BCMA-targeted therapies;
  • Preclinical proof-of-concept of BCMA blockade;
  • Clinical experience with BCMA-targeted therapies;
  • The competitive landscape of BCMA-targeted treatment modalities;
  • Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
  • Profiles of companies involved in develompent of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity. As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.



B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Table of Contents

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Indications & Treatment Options

5          Clinical Experience with BCMA-Targeted Treatment Modalities

6          Treatment Modalities & Competitive Landscape

7          Drug & Cell Therapy Candidate Profiles
7.1       CAR T-Cells
7.2       Antibody-Drug Conjugate (ADC)
7.3       T-Cell Redirecting Antibodies

8          Company Profiles

9          References


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up